151. A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model
- Author
-
Ping Wang, Jianzhong Bi, Jun-Ying Miao, Shunliang Xu, Zhaohong Xie, CuiPing Zhao, Hongna Yang, ShaoNan Yang, Bao-Xiang Zhao, LiFei Wei, and Hui Yang
- Subjects
Genetically modified mouse ,medicine.medical_specialty ,Amyloid ,Transgene ,Mice, Transgenic ,Biology ,Insulysin ,Pathogenesis ,Amyloid beta-Protein Precursor ,Mice ,4-Butyrolactone ,Alzheimer Disease ,Internal medicine ,Insulin-degrading enzyme ,medicine ,Autophagy ,Presenilin-1 ,Animals ,Maze Learning ,Neprilysin ,PI3K/AKT/mTOR pathway ,Memory Disorders ,Amyloid beta-Peptides ,General Neuroscience ,Brain ,General Medicine ,Cell biology ,Psychiatry and Mental health ,Clinical Psychology ,Disease Models, Animal ,Endocrinology ,Geriatrics and Gerontology ,Signal Transduction - Abstract
Excessive extracellular deposition of amyloid- peptide (Aβ) in the brain is the pathological hallmark of Alzheimer's disease (AD). Cumulative evidence indicates that autophagy is involved in the metabolism of Aβ and pathogenesis of AD. However, the molecular mechanism underlying the pathogenesis of AD is not yet well defined, and there has been no effective treatment for AD. We recently found that long-term treatment with a butyrolactone derivative 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran- 2(3 H)-one (3BDO) increased levels of insulin-degrading enzyme and neprilysin, suppressed autophagy via an mTOR pathway, lowered levels of Aβ, and prevented AD-like cognitive deficits in the AβPP/PS1 double transgenic mouse model. Therefore, our findings suggest that 3BDO may be beneficial in the prevention and treatment of AD.
- Published
- 2012